CO-VELOCITY-GLOBAL
Velocity Global , the leading provider of global expansion solutions, has selected Amsterdam, Netherlands, as the location for its European headquarters. The Denver-based company appointed Sander Poos as managing director of Europe based in Amsterdam.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901006149/en/
As an International PEO, Velocity Global serves as an Employer of Record for supported employees in countries where clients have not set up a legal entity, enabling companies to compliantly expand internationally in a matter of weeks, and reduce their expansion costs.
“The number of clients expanding in Europe more than doubled this year compared to the same period in 2019,” said Velocity Global founder and CEO Ben Wright. “Even amidst a global pandemic, our growing clients also doubled the number of supported employees onboarded in Europe this year compared to the same period last year. Europe is critically important for both Velocity Global and our clients.”
The uptick in volume supports findings in Velocity Global’s 2020 State of Global Expansion™ report that 41 percent of tech companies in the U.S. and the UK targeted Europe as the most promising market to grow their customer base.
Amsterdam emerged as the natural choice for Velocity Global’s European headquarters as a business-friendly, culturally attractive city for international commerce. The city is geographically adjacent to key markets like Germany, France, and the United Kingdom. This year, in the final months of the Brexit transition, the European Union received approximately 80 percent of the European growth among Velocity Global clients, while the UK remains the top individual country destination.
Velocity Global established its Amsterdam presence in 2018, and now employs more than 30 team members in Europe serving in corporate and client-facing functions including client experience, employee support, operations, compliance, sales, finance, human resources, and legal.
Sander Poos leads Velocity Global’s team throughout Europe, reporting to Chief Operating Officer José Montero. He adds 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. Poos most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously he held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
“Sander brings a breadth of experience in successfully building people-focused business solutions across Europe,” said Montero. “His leadership balances revenue operations with industry-leading customer experience platforms putting people at the heart of his strategy.”
“New supported employees in Europe represent close to half of our global onboardings this year, a 40 percent increase over the first eight months of 2019,” said Poos. “I am excited to lead European growth for Velocity Global and our clients.”
The company's European team supports 19 languages from Europe, the Middle East, Africa, and Asia, contributing to the 36 languages supported worldwide by Velocity Global. Velocity Global has 250 employees located in 14 countries serving thousands of supported employees for clients in over 100 countries.
ABOUT VELOCITY GLOBAL
Velocity Global is the leading provider of global employment solutions that has reinvented the way companies expand overseas. With unrivaled expertise in over 185 countries, Velocity Global delivers end-to-end services and best-in-class support to help companies confidently navigate the entire lifecycle of international business. To ensure a compliant, efficient, and flexible international expansion, Velocity Global provides a comprehensive suite of global services that includes International PEO, Entity Setup and Support, Global Talent Acquisition, Immigration, and Consulting.
ABOUT SANDER POOS
Sander leads Velocity Global’s European team, responsible for the company’s business activities in the region, including all operations functions, customer experience, service delivery, and partner network alignment. He is a Dutch native based at the company’s European regional headquarters in Amsterdam.
Sander applies 25 years of experience in sales and operations in the human resources and software-as-a-service (SaaS) sectors. He most recently served as managing director of Benelux for Indeed.com, supporting operations in Amsterdam and Brussels as well as Dublin, Ireland. Previously, Sander held leadership positions for companies including Xerox, Adecco, Monster.com, and Telegraaf Media Group.
He received dual university degrees in Labor Market Politics and Personnel Policy, and Catholic Teaching from HAS Den Bosch University Holland, and an MBA from the Imperial College Business School in London. In his free time, he enjoys spending time with his family and playing tennis, and serves on the Board of the Dutch Tennis Association.
See biographies for Velocity Global leaders here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom